Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

Latest from Memorial Sloan Kettering Cancer Center


Managing Adverse Events and Toxicities HER2+ Metastatic Breast Cancer

June 03, 2024

Tiffany A. Traina, MD, addresses adverse event monitoring and the range of adverse events patients may experience with front-line treatments for HER2-positive metastatic breast cancer, particularly highlighting alopecia and diarrhea as common side effects.

Evidence-Based Sequencing for HER2+ mBC After Progression: Clinical Trial Data and NCCN Guideline Updates

June 03, 2024

Key opinion leaders explore various therapeutic options for later-line treatment of HER2-positive metastatic breast cancer, emphasizing the significance of the HER2CLIMB and CLEOPATRA trials, while also drawing comparisons to real-world data to inform clinical decision-making.

First-Line HER2+ Metastatic Breast Cancer Trials in Focus

May 28, 2024

Heather McArthur, MD, emphasizes the influence of recent and ongoing clinical trials, specifically DESTINY-Breast09 and HER2CLIMB-05, in steering the treatment paradigm in 1st-line HER2-positive metastatic breast cancer.

Evolution of the HER2+ Metastatic Breast Cancer Treatment Landscape

May 20, 2024

Medical experts examine the current standards of care and successive lines of treatment for HER2-positive metastatic breast cancer, while also addressing the challenges encountered in managing this complex disease.

The Role of HER2 in Breast Cancer and Treatment Goals for HER+ Metastatic Breast Cancer Patients

May 20, 2024

Tiffany A. Traina, MD; Vijayakrishna Gadi, MD, PhD, and Heather McArthur, MD, underscore the importance of testing all early-stage and breast cancer patients for HER2 positivity to inform and guide optimal therapeutic decision-making.